Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas
Authors:
Open Access
- 18 March 2018
- journal article
- research article
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 1 (1) , 30-47
Abstract
Aim: CD22 Delta E12 as an oncogenic driver lesion in aggressive and drug-resistant B-precursor acute lymphoblastic leukemia (BPL) cells. The purpose of the present study was to identify the CD22 Delta E12-specific signature transcriptome in human BPL cells and evaluate the clinical potential of a nanoscale formulation of CD22 Delta E12-siRNA as an RNAi therapeutic against drug-resistant BPL. CD22 Delta E12-siRNA nanoparticles significantly improved the event-free survival (EFS) outcome of NOD/SCID (NS) mice challenged with human BPL xenograft cells. Methods: Gene expression and translational bioinformatics methods were applied to examine the expression of the CD22 Delta E12-specific signature transcriptome in human BPL cells in subsets of BPL patients. Survival analysis for mice challenged with BPL cells and treated with CD22 Delta E12-siRNA was performed using standard methods. Results: Leukemia cells from CD22 Delta E12-Tg mice exhibit gene and protein expression profiles consistent with constitutive activation of multiple signaling networks, mimicking the profiles of relapsed BPL patients as well as newly diagnosed high-risk patients with BCR-ABL(+)/Philadelphia chromosome (Ph)(+) BPL as well as Ph-like BPL. A nanoscale formulation of CD22 Delta E12-siRNA abrogated the in vivo clonogenicity of the leukemia-initiating leukemic cell fraction in xenograft specimens derived from patients with relapsed BPL and significantly improved the EFS outcome of NS mice challenged with drug-resistant human BPL xenograft cells. Conclusion: The CD22-RNAi technology is applicable to all BPL patients both high risk and standard risk. That is because CD22 Delta E12 is a characteristic feature of drug-resistant leukemic clones that escape chemotherapy and cause relapse in both high risk and low risk subgroups of patients. The technology therefore has the potential (1) for prevention of relapses by selectively killing the clones that are most likely to escape chemotherapy and cause relapse as well (2) for treatment of relapses in BPL. This research project may also lead to innovative salvage regimens against other forms of CD22 Delta E12-positive relapsed B-lineage leukemias and lymphomas.Keywords
This publication has 19 references indexed in Scilit:
- Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALLBlood, 2013
- How I treat relapsed childhood acute lymphoblastic leukemiaBlood, 2012
- Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?Blood, 2012
- Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategiesBlood, 2011
- CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemiaBritish Journal of Haematology, 2011
- Recombinant human CD19‐ligand protein as a potent anti‐leukaemic agentBritish Journal of Haematology, 2011
- CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemiaProceedings of the National Academy of Sciences, 2010
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyThe Lancet Oncology, 2009
- Progress in Childhood Cancer: 50 Years of Research Collaboration, a Report From the Children's Oncology GroupSeminars in Oncology, 2008
- Long-Term Outcome in Children With Relapsed ALL by Risk-Stratified Salvage Therapy: Results of Trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group 87Journal of Clinical Oncology, 2005